Crispr Appears 'Crispy and Overcooked,' Says Analyst

(Bloomberg) -- Investors who eagerly chased Crispr Therapeutics AG’s scorching run this year may want to slam on the brakes.

Bloomberg Quint

Add BloombergQuint App to Home screen.